Viewing Study NCT04754412



Ignite Creation Date: 2024-05-06 @ 3:46 PM
Last Modification Date: 2024-10-26 @ 1:57 PM
Study NCT ID: NCT04754412
Status: RECRUITING
Last Update Posted: 2024-05-09
First Post: 2021-02-10

Brief Title: Culturally Based Brief Expressive Writing Intervention for the Improvement of Health in Chinese Immigrant Stage 0-III Breast Cancer Survivors Writing to Heal Study
Sponsor: MD Anderson Cancer Center
Organization: MD Anderson Cancer Center

Study Overview

Official Title: Writing to Heal A Culturally Based Brief Expressive Writing Intervention for Chinese Immigrant Breast Cancer Survivors
Status: RECRUITING
Status Verified Date: 2024-05
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This clinical trial studies the effect of a culturally based brief expressive writing intervention in improving the health of Chinese immigrant stage 0-III breast cancer survivors Culturally based brief expressive writing interventions may help researchers learn more about the experiences of Chinese immigrant breast cancer survivors and how writing about their experiences may affect their health
Detailed Description: PRIMARY OBJECTIVES

I To determine the health benefits of expressive writing compared with the control condition

II To characterize how acculturation moderates the effects of expressive writing interventions

III To identify mechanisms explaining the benefits of the interventions using mixed methods

OUTLINE Patients are randomized to 1 of 3 arms

ARM I CONTROL Patients write about facts regarding their cancer diagnosis and treatment for 3 weekly 30-minute sessions

ARM II SELF-REGULATION Patients write about stress and coping emotional disclosure and benefit finding for 3 weekly 30-minute sessions

ARM III SELF-CULTIVATION Patients write about positive thoughts and feelings regarding their breast cancer experience for 3 weekly 30-minute sessions

After completion of study patients are followed up at 6 weeks and at 6 and 12 months

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
NCI-2020-14096 REGISTRY None None
2020-0708 OTHER M D Anderson Cancer Center None